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Introduction
Despite its application for almost 20 years, no agreement has
been reached on the indications for continuous intraperitoneal
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Abstract
Aims To evaluate the effects of continuous intraperitoneal insulin infusion
(CIPII) using implantable pumps on glycaemic control and duration of hospital
stay in poorly controlled ‘brittle’ Dutch diabetes patients, and to assess their
current quality of life.
Methods Thirty-three patients were included. Glycaemic control was retro-
spectively assessed with HbA1c levels acquired before implantation, 1 year later
and at long-term follow up of 58 months. Duration of hospital stay the year
before and the year following first implantation was extracted from hospital
records. Determinants of long-term glycaemic response were sought. Self-report
questionnaires were administered at 58 months follow-up only, to assess
current psychopathology and quality of life.
Results Mean HbA1c decreased from 10.0 ± 2.3% to 9.0 ± 1.8% (P = 0.039)
1 year after implantation and stabilized at 9.0 ± 1.6% (P = 0.023) during long-
term follow-up. Median number of hospital days in the 20 patients suffering
from hospital admission before implantation decreased from 45 the year before
implantation to 13 the year after (P = 0.005). Patients with a higher baseline
HbA1c showed a larger long-term response (P < 0.001). Relatively low levels for
quality of life were found, as well as a higher than expected number of patients
with psychiatric symptoms.
Conclusions CIPII proved effective in complex patients with a history of poor
control and hospital admission. Despite a substantial long-term improvement in
glycaemic control and diminished hospital stay, normal levels of glycaemic con-
trol and quality of life were not attained.
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insulin infusion using implantable pumps (CIPII). CIPII is
mostly used in France, where the initial research focused on its
feasibility and safety aspects. Currently, compliant patients in
reasonably good glycaemic control qualify for this form of
therapy [1]. The main demonstrable benefit of CIPII has been
the low number of severe hypoglycaemic events: at a mean
HbA1c level of 6.8%, the number of severe hypoglycaemic epi-
sodes was 2.5 per 100 patient years [2]. This compares favour-
ably with the intensively treated group of the Diabetes Control
and Complications Trial (DCCT), where this rate was 62 per
100 patient years, at a similar level of glycaemic control [3]. A
modest benefit in terms of glycaemic control was reported in
the French study of 224 patients, with an HbA1c decrement of
0.5% after 1 year on CIPII treatment. Other studies included
patients in fairly good glycaemic control [4–10] or exluded
patients who had suffered from recurrent severe hypoglycae-
mia or significant long-term diabetic complications [11–13].
In contrast, in The Netherlands, CIPII has been used since
1986 as a ‘last resort’ treatment, i.e. when multiple injection
and/or subcutaneous pump therapy has failed. Predominantly,
so called ‘brittle’ patients in very poor glycaemic control and
often following long and/or recurrent hospital admissions
have received an implant. To date, the efficacy of CIPII using
this Dutch approach has not been described. We report here on
glycaemic results, length of hospital stay and perceived health-
related quality of life in patients treated with CIPII in The
Netherlands. Furthermore, we sought potential determinants
of glycaemic response to CIPII.
Patients and methods
The protocol was approved by the respective institutional Eth-
ics Committees.
Patients
At the time of inclusion, a total of 41 patients was treated with
CIPII in The Netherlands. Thirty-four were treated in one of the
three centres caring for more than three patients. These 34
patients were asked to participate by their treating physician.
Thirty-three patients (Zwolle n = 20, Amsterdam n = 7 and
Roermond n = 6) gave informed consent, one patient refused to
participate. Two patients, in whom an implantable pump was
explanted, were not included in the investigation. In one patient
suffering from Werner’s syndrome, characterized by the absence
of subcutaneous fat, the pump was explanted because of a
pump pocket infection. Another pump was explanted, a few
weeks following implantation, on the patient’s request because
of local complaints and psychological problems.
Biomedical measures
Glycaemic control and hospital stay were assessed retrospect-
ively from hospital records. HbA1c values (ion-exchange
high-performance liquid chromatography, reference value
4.3–6.1%) were measured prior to pump implantation (mean
of all values in the year before implantation, median 1 (25–
75th%: 1–2) measurement per patient), 1 year after implanta-
tion (mean of all values measured from 9 to 15 months after the
first implantation, median 2 (25–75th%: 1–2) measurements
per patient) and at the time of the investigation (mean of all
values measured in the 6 months before completing the question-
naires, after a mean follow-up of 58 months on CIPII, median
1 (25–75th%: 1–2) measurement per patient). In patients who
were admitted to the hospital in the year before implantation
because of ‘brittle’ diabetes (n = 20), the number of hospital
days in the year before implantation was compared with the
number of days in the first year following implantation, start-
ing 2 days before implantation. The following diabetic compli-
cations were classified on the basis of the patients’ medical
records: retinopathy (background or proliferative/lasered),
clinically manifest polyneuropathy and nephropathy (micro-
albuminuria, i.e. urinary albumin 30–300 mg/24 h, or pro-
teinuria, i.e. urinary albumin > 300 mg/24 h and/or serum
creatinine > 150 µmol/ l).
Psychosocial measures
Data on demographic and medical background, on psycho-
logical dysfunction and on health-related quality of life were
gathered only at the time of the investigation, after a mean
of 58 months on CIPII. No baseline measures before starting
CIPII were taken. Self-report questionnaires were introduced to
the patient by a diabetes nurse specialist and filled out by the
patient during an out-patient clinic visit.
The questionnaire on demographic and medical background
contained questions covering ethnic background, marriage status,
educational level, disablement (i.e. legally only partly capable
of work), comorbidity, psychiatric history, and frequency of
self-monitoring of blood glucose. Results were compared with
means obtained in a large survey of Dutch diabetes patients
(n = 1472, 51% Type 1 diabetes patients, 49% female) [14].
The Symptom Checklist 90 (SCL-90) is a widely used
90-item questionnaire, that provides a global severity index of
psychological dysfunction, comprising eight major subscales:
depression, anxiety, phobic anxiety, hostility, somatization,
interpersonal sensitivity, insufficiency of thought or behaviour
(compulsive–obsessive behaviour) and sleeping problems. The
percentage of patients scoring ≥ 80th percentile (i.e. the high or
very high range, as defined in the SCL-90 manual, and differ-
entiated to sex) was compared with the expected 20% found
in a normal reference population [15]. The global severity index
was compared with reference values from a Dutch population-
based sample of 907 subjects [16].
The following instruments were used to assess health related
quality of life;
• Medical Outcome Study 36-Item Short Form Survey (SF-36)
[17]. The generic SF-36 measures eight health concepts:
physical functioning, physical role functioning, social func-
tioning, bodily pain, mental health, emotional role function-
ing, vitality, and general health perceptions. We compared
the mean scores with mean scores of two reference groups:
patients with complicated diabetes or complicated coronary
artery disease (n = 144), and patients with both depressive
symptoms and complicated medical conditions (n = 43) [18].
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• The Diabetes Quality of Life Measure (DQOL) has four
scales: satisfaction with current mode of therapy, impact of
diabetes and treatment on living, social /vocational worry,
and diabetes worry [19]. Mean scores were compared with
those found in 684 intensively treated Type 1 patients of the
DCCT study [20].
• The 20-item Problem Areas In Diabetes (PAID) scale meas-
ures diabetes-related distress [21]. Results were compared
with scores obtained in a sample (n = 739) of Dutch Type 1
diabetes patients [22].
Statistical analysis
HbA1c levels and length of hospital stay were analysed using
paired samples t-test and the Wilcoxon signed rank test, respect-
ively. Independent samples t-test was used to test for differences
between mean scores of our patients and reference groups.
A difference in long-term glycaemic response (the difference
between HbA1c at 58 months of CIPII and baseline) was sought
between those with an HbA1c before implantation above or
below the group mean, using the Mann–Whitney test. In order to
identify characteristics of those patients without any, or on the
contrary a large improvement in glycaemic control, we used
univariate linear regression analysis to explore the following
possible determinants of long-term glycaemic response: sex,
age at first implant, type of diabetes, frequency of self monitor-
ing of blood glucose, duration of hospital stay in the year before
implantation, presence of a psychiatric history, and the global
severity index and depression subscale of the SCL-90. P-values
< 0.05 were considered statistically significant. Data are
presented as means ± SD or median (25%, 75%). Analyses
were performed using the SPSS 9.0 [23] and confidence interval
analysis [24].
Results
Clinical features, glycaemic control and hospital stay
Clinical characteristics of the 33 patients are shown in Table 1.
Before CIPII, all patients had been treated with intensive insulin
therapy. Intensification of insulin injection treatment and/or
continuous subcutaneous insulin infusion had been attempted in
all patients, before a pump was implanted. Mean HbA1c decreased
significantly during the first year on CIPII from 10.0 ± 2.3%
before to 9.0 ± 1.8% after 1 year, P = 0.039. This improve-
ment persisted, with a long-term mean HbA1c at 58 ± 27
months follow-up of 9.0 ± 1.6%, P = 0.023 compared with
before implantation. In the 20 patients who had hospital admis-
sion before implantation, the median duration of hospital stay
was significantly reduced from 45 (19 to 114) days in the year
before implantation to 13 (9–25) days in the year after
(P = 0.005), the latter mostly due to the admission for implan-
tation. At the time of the investigation, all patients were treated
with a Minimed device (Minimed; Sylmar, CA, USA), although
two had begun on an Infusaid device (Norwood, MA, USA).
Demographic and background clinical data
All patients were born in The Netherlands. Twenty-two
(66.7%) patients were married or cohabiting with a partner.
Twenty-seven patients (81.8%) had high school as their
highest completed educational level, six patients (18.2%)
completed college or university. These frequencies are similar
to those found in a large survey of Dutch diabetes patients:
77.9% and 22.1%, respectively [14]. Disablement existed in
17 (52%) patients. Complete disablement existed in 12 (36%)
of these patients. Twenty-six (79%) patients reported one or
more comorbid conditions: hypertension (n = 11, 33.3%),
chronic gastrointestinal disorders (n = 11, 33.3%) and chronic
fatigue (n = 9, 27.3%). Four patients (12%) were currently
under treatment of a psychologist or psychiatrist. Patients
reported a mean frequency of home blood glucose measure-
ments during CIPII of four times a day.
Psychological dysfuntion (see Table 2)
On the SCL-90, the percentage of patients scoring ≥ 80th
percentile of the scores in the normal reference population was
51.6% on the subscale somatization, 48.3% on the subscale
insufficiency of thought or behaviour, and 42.4% on the
depression subscale. On the other subscales, the percentage
was around the expected 20% (data not shown).
Health-related quality of life measures (see Table 2 and Fig. 1)
Generic health-related quality of life (Fig. 1)
Mean scores on the subscales of the SF-36 Health Survey
for physical functioning and mental health were similar to the
reference values for patients with serious complicated diabetes
or coronary artery disease (57.1 ± 30.5 vs. 57.4 ± 28.1, P = NS
and 71.4 ± 22.0 vs. 77.6 ± 15.8, P = NS, respectively). Mean
scores were in the psychiatric range for the subscales general
health, pain and social functioning (40.1 ± 22.6 vs.
39.9 ± 15.1, P = NS; 50.6 ± 30.0 vs. 50.2 ± 23.1, P = NS; and
59.9 ± 32.6 vs. 65.1 ± 22.6, P = NS, respectively).
Table 1 Clinical characteristics of the study population
n 33
Male/female 9/24
Age (years) 42.6 ± 13.3
Type 1 diabetes (n; %) 28 (84.8)
Diabetes duration (years) 20.5 ± 8.4
Retinopathy
Background retinopathy (n; %) 19 (57.6)
Proliferative retinopathy (n; %) 7 (21.2)
Nephropathy
Microalbuminuria (n; %) 7 (21.2)
Proteinuria (n; %) 3 (9.1)
Creatinine > 150 µmol/l 2 (6.1)
Neuropathy 19 (57.6)
Data are presented as means ± SD, n or n (%).
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Diabetes-specific health-related quality of life
For all four subscales of the Diabetes Quality of Life Measure-
ment (DQOL), the patients reported a poor quality of life
compared with the patients in the DCCT cohort. As measured
using the Problem Areas In Diabetes (PAID) scale, our patients
did not report significantly different levels of diabetes-related
emotional distress, compared with those found earlier in
Dutch diabetes patients.
Determinants of long-term glycaemic response
The long-term glycaemic response in those with an HbA1c
before implantation above the group mean (> 10.0%) was
larger than in those below the group mean (< 10.0%): median
2.30% (0.8%, 4.70%) vs. 0.2% (–1.0%, 0.71%), respectively
(P < 0.001). At univariate linear regression analyses, to iden-
tify characteristics of patients who reacted very well or not at
all to CIPII, sex, age at first implant, type of diabetes, frequency
of self monitoring of blood glucose, duration of hospital stay
the year before implantation, presence of a psychiatric history,
and the global severity index and depression subscale of the
SCL-90 were not found to be significant determinants of long-
term glycaemic response (data not shown).
Discussion
We found a substantial improvement in glycaemic control (1%
reduction of HbA1c) following implantation of an insulin pump
in ‘brittle’ patients in poor control. Although the mean HbA1c
level on CIPII remained unsatisfactorily high at 9.0%, this differ-
ence, sustained over 5 years, will have reduced long-term diabetic
complication rates. Furthermore, a large decline in duration of
hospital stay was seen following the start of CIPII.
Also, after almost 5 years on CIPII, we found relatively low
levels of quality of life, as well as a higher than expected
number of patients with psychiatric symptoms in our group.
Low quality of life in diabetes patients has been shown to be
related to psychiatric symptoms [25] as well as the presence of
long-term diabetic complications [26]. Both were present in
our group. A relationship between poor glycaemic control and
low health-related quality of life has been denied by both the
DCCT investigators and others [20,27]. In the DCCT, the
conventionally treated group showed a much better health-
related quality of life, measured with the same instruments we
used, at a comparable level of glycaemic control as in our patients.
We therefore hypothesize that our patients had pre-existing
low coping abilities and social functioning. When they were
affected by diabetes they were not able to cope with the
demands imposed by this chronic disease and fared poorly, but
their burden of disease was partially relieved by CIPII.
Earlier studies have reported improved health-related
quality of life following start of CIPII [6,10]. It is likely that
health-related quality of life improved in our group, certainly
in those who suffered from hospital admissions before implan-




patients (n = 33) Reference groups
SCL-90 (0–450, highest 
psychological dysfunction) Normal population
Global Severity Index 140.6 ± 41.1 125.0 ± 30.3*
DQOL (0–100, highest quality of life) DCCT cohort
Impact of diabetes 61.8 ± 13.4 75 ± 8*
Satisfaction 64.5 ± 17.0 74 ± 3*
Social worry 68.2 ± 25.4 78 ± 16*
Diabetes worry 70.3 ± 17.6 81 ± 13*
Dutch Type 1 patients
PAID (0–100, highest distress) 28.6 ± 19.0 24.6 ± 18.7
Data are presented as means ± SD.
*P-value ≤ 0.05.
CIPII, Continuous intraperitoneal insulin infusion; SCL-90, Symptom Check List-90; DQOL, 
diabetes quality of life measure; DCCT, Diabetes Control and Complications Trial; PAID, problem 
areas in diabetes.
Table 2 Mean scores on the questionnaires in 
the study population and various reference 
groups
Figure 1 SF-36 scores of our study population () compared with two 
SF-36 reference groups: a group of 43 depressive patients with a serious 
chronic medical condition () and a group of 144 non-depressive 
patients with complicated diabetes or coronary artery disease (hatched).
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of a baseline measurement. Therefore the quality of life data
can serve only to illustrate the major impact of disease in this
group, and that normalization of scores was not attained.
For a group of ‘brittle’ patients, who regularly skip insulin
injections [28], CIPII may be an acceptable mode of treatment.
Using this instrument, a more secure insulin delivery can
probably be established. This may result in a more stable and
improved glycaemic control, but may not improve psychoso-
cial stress.
Since CIPII is relatively expensive and laborious, the identi-
fication of predictors for successful application would be of
great value. The glycaemic response was larger in those with
higher baseline HbA1c. Therefore, CIPII is not contraindicated
in these patients, as one might have predicted. No other factors
predicting a positive or negative glycaemic effect could be
identified. This suggests that intuitive contraindications for
CIPII, e.g. presence of a history of psychiatric treatment, do
not necessarily prevent better glycaemic control. Overall, for
patients in persistent poor control, suffering frequent
hospitalization, CIPII seems a reasonable option. However,
good glycaemic control and quality of life can be reached only
in a minority.
The predominance of female subjects in our group is strik-
ing. The burden of diabetes may be larger in women [29], and
most ‘brittle’ diabetes patients in other reported series are
female [30]; nine of our female patients received their first
implant before the age of 30 years.
We did not gather any information on technical complica-
tions, as our retrospective data would not have added to the
prospective data of the French registry [31]. Following the
introduction of a more stable insulin, with less tendency to
aggregate, catheter obstruction, the most frequent complica-
tion, is rarely seen [32].
A limitation of French, US and Dutch studies on CIPII is the
absence of large-scale controlled trials. When applied as a last
resort, a control group is not appropriate. However, prospect-
ive controlled trials should be carried out, for those with both
good and poor control, and should measure cost-effectiveness.
In conclusion, this ‘Dutch experience’ suggests that very
poor glycaemic control and repeated hospital admissions due
to diabetes are reasonable indications for CIPII.
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